Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease - PubMed (original) (raw)
. 2015 Aug;21(8):1373-83.
doi: 10.1016/j.bbmt.2015.04.016. Epub 2015 May 11.
Ying Taur 2, Sean M Devlin 3, Doris M Ponce 4, Jenna D Goldberg 4, Katya F Ahr 5, Eric R Littmann 6, Lilan Ling 5, Asia C Gobourne 5, Liza C Miller 5, Melissa D Docampo 5, Jonathan U Peled 4, Nicholas Arpaia 5, Justin R Cross 7, Tatanisha K Peets 8, Melissa A Lumish 5, Yusuke Shono 5, Jarrod A Dudakov 5, Hendrik Poeck 5, Alan M Hanash 4, Juliet N Barker 4, Miguel-Angel Perales 4, Sergio A Giralt 4, Eric G Pamer 2, Marcel R M van den Brink 4
Affiliations
- PMID: 25977230
- PMCID: PMC4516127
- DOI: 10.1016/j.bbmt.2015.04.016
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
Robert R Jenq et al. Biol Blood Marrow Transplant. 2015 Aug.
Abstract
The relationship between intestinal microbiota composition and acute graft-versus-host disease (GVHD) after allogeneic blood/marrow transplantation (allo-BMT) is not well understood. Intestinal bacteria have long been thought to contribute to GVHD pathophysiology, but recent animal studies in nontransplant settings have found that anti-inflammatory effects are mediated by certain subpopulations of intestinal commensals. Hypothesizing that a more nuanced relationship may exist between the intestinal bacteria and GVHD, we evaluated the fecal bacterial composition of 64 patients 12 days after BMT. We found that increased bacterial diversity was associated with reduced GVHD-related mortality. Furthermore, harboring increased amounts of bacteria belonging to the genus Blautia was associated with reduced GVHD lethality in this cohort and was confirmed in another independent cohort of 51 patients from the same institution. Blautia abundance was also associated with improved overall survival. We evaluated the abundance of Blautia with respect to clinical factors and found that loss of Blautia was associated with treatment with antibiotics that inhibit anaerobic bacteria and receiving total parenteral nutrition for longer durations. We conclude that increased abundance of commensal bacteria belonging to the Blautia genus is associated with reduced lethal GVHD and improved overall survival.
Keywords: Graft-versus-host disease; Intestinal bacteria.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Figures
Figure 1
Changes in the intestinal flora are associated with differences in GVHD-related mortality. A) Bacterial diversity was quantified using the inverse Simpson index following composition analysis of stool samples from Cohort 1 performed by 16S gene sequencing. Patients were stratified by the median diversity index value and analyzed for cumulative incidence of GVHD-related mortality. B) Associations of bacterial genera with GVHD-related mortality outcomes were quantified by LEfSe analysis. Position along the vertical axis indicates statistical significance. C) Patients from Cohorts 1 and 2 were stratified by median Blautia abundance (0.05% in both) and analyzed for incidence of GVHD-related mortality.
Figure 2
A) Association of Blautia abundance and outcomes after allo BMT. Patients from the two flora cohorts were combined and stratified by Blautia abundance below or above 0.05%, and evaluated for the indicated outcomes; similar results were seen for each individual cohort (not shown). B) Blautia abundance (left), survival, and cause of death (right) are indicated for individual patients from two cohorts combined, ranked by Blauita abundance.
Figure 3
Association of Blautia abundance with clinical acute GVHD. A) Patients were stratified by Blautia abundance below or above 0.05%, and evaluated for development of the indicated severity grades of acute GVHD, as well as acute GVHD that required systemic therapy with corticosteroids. B) Patients were evaluated for development of acute GVHD in typical target organs.
Figure 4
Identifying potential determinants of Blautia abundance in allo BMT patients. A) Left: Blautia abundances in all available stool samples from both flora cohorts. An abundance trend was constructed using moving average filtering (solid blue line; 95% confidence intervals shown in gray). Middle and Right: Serial fecal sample composition analysis from two representative patients. Vertical bars indicate composition of fecal microbiota by the indicated taxa. Horizontal bars indicate antibiotic and TPN exposures. Flora composition and time courses of antibiotic and TPN exposure for all patients are shown in Figure S2. Abbreviations: intravenous (IV), oral (PO), piperacillin-tazobactam (pip-tazo), trimethoprim-sulfamethoxazole (tmp-smx), total parenteral nutrition (TPN). B) Patients were subsetted by exposure to antibiotics with anaerobic coverage prior to sample collection, and duration of TPN therapy, and Blautia abundance was evaluated. Horizontal bars indicate median Blautia abundance. C) A subset of patients who were not exposed to antibiotics with anaerobic coverage prior to sample collection were further subsetted by duration of TPN therapy and evaluated for Blautia abundance in a stool sample prior to day 12 and from day 12.
Similar articles
- Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation.
Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Müller KD, Quabeck K, Sayer HG, Graeven U, Mahmoud HK, Schaefer UW. Beelen DW, et al. Blood. 1992 Nov 15;80(10):2668-76. Blood. 1992. PMID: 1421380 - Alteration of Gut Microbiota Composition and Diversity in Acute and/or Chronic Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study.
Gavriilaki E, Christoforidi M, Ouranos K, Minti F, Mallouri D, Varelas C, Lazaridou A, Baldoumi E, Panteliadou A, Bousiou Z, Batsis I, Sakellari I, Gioula G. Gavriilaki E, et al. Int J Mol Sci. 2024 May 26;25(11):5789. doi: 10.3390/ijms25115789. Int J Mol Sci. 2024. PMID: 38891979 Free PMC article. - Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R, Palaniyandi S, Hildebrandt GC. Kumari R, et al. Dig Dis Sci. 2019 Mar;64(3):669-677. doi: 10.1007/s10620-018-5369-9. Epub 2018 Dec 7. Dig Dis Sci. 2019. PMID: 30523482 Review. - The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.
Staffas A, Burgos da Silva M, van den Brink MR. Staffas A, et al. Blood. 2017 Feb 23;129(8):927-933. doi: 10.1182/blood-2016-09-691394. Epub 2016 Dec 9. Blood. 2017. PMID: 27940475 Free PMC article. Review.
Cited by
- Microbiota dysbiosis and functional outcome in acute ischemic stroke patients.
Chang Y, Woo HG, Jeong JH, Kim GH, Park KD, Song TJ. Chang Y, et al. Sci Rep. 2021 May 26;11(1):10977. doi: 10.1038/s41598-021-90463-5. Sci Rep. 2021. PMID: 34040060 Free PMC article. - Nutritional modulation of the gut microbiome in allogeneic hematopoietic stem cell transplantation recipients.
Muratore E, Leardini D, Baccelli F, Venturelli F, Prete A, Masetti R. Muratore E, et al. Front Nutr. 2022 Oct 20;9:993668. doi: 10.3389/fnut.2022.993668. eCollection 2022. Front Nutr. 2022. PMID: 36337625 Free PMC article. Review. - A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.
Ponce DM, Alousi AM, Nakamura R, Slingerland J, Calafiore M, Sandhu KS, Barker JN, Devlin S, Shia J, Giralt S, Perales MA, Moore G, Fatmi S, Soto C, Gomes A, Giardina P, Marcello L, Yan X, Tang T, Dreyer K, Chen J, Daley WL, Peled JU, van den Brink MRM, Hanash AM. Ponce DM, et al. Blood. 2023 Mar 23;141(12):1389-1401. doi: 10.1182/blood.2021015111. Blood. 2023. PMID: 36399701 Free PMC article. Clinical Trial. - Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes.
Li YN, Kang NL, Jiang JJ, Zhu YY, Liu YR, Zeng DW, Wang F. Li YN, et al. World J Gastroenterol. 2022 Sep 21;28(35):5188-5202. doi: 10.3748/wjg.v28.i35.5188. World J Gastroenterol. 2022. PMID: 36188719 Free PMC article. - Rare transmission of commensal and pathogenic bacteria in the gut microbiome of hospitalized adults.
Siranosian BA, Brooks EF, Andermann T, Rezvani AR, Banaei N, Tang H, Bhatt AS. Siranosian BA, et al. Nat Commun. 2022 Jan 31;13(1):586. doi: 10.1038/s41467-022-28048-7. Nat Commun. 2022. PMID: 35102136 Free PMC article.
References
- Pasquini MC, W Z. Current use and outcome of hematopoietic stem cell transplantation. CIBMTR Summary Slides. 2013 Available at: http://www.cibmtr.org.
- Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res. 1971;45:577–88. - PubMed
- van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974;52:401–4. - PubMed
- Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983;308:302–7. - PubMed
- Vossen JM, Heidt PJ, van den Berg H, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis. 1990;9:14–23. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 AI101406/AI/NIAID NIH HHS/United States
- R25 CA020449/CA/NCI NIH HHS/United States
- P01-CA023766/CA/NCI NIH HHS/United States
- T32 CA009207/CA/NCI NIH HHS/United States
- R01-AI095706/AI/NIAID NIH HHS/United States
- R01-HL069929/HL/NHLBI NIH HHS/United States
- R01-AI042135/AI/NIAID NIH HHS/United States
- R01 AI100288/AI/NIAID NIH HHS/United States
- P30-CA008748/CA/NCI NIH HHS/United States
- R01 AI042135/AI/NIAID NIH HHS/United States
- R01-AI101406/AI/NIAID NIH HHS/United States
- R01-AI080455/AI/NIAID NIH HHS/United States
- HHSN272200900059C/AI/NIAID NIH HHS/United States
- R01 HL069929/HL/NHLBI NIH HHS/United States
- P30 CA072720/CA/NCI NIH HHS/United States
- K23-AI095398/AI/NIAID NIH HHS/United States
- P01 CA023766/CA/NCI NIH HHS/United States
- K23 AI095398/AI/NIAID NIH HHS/United States
- R01 AI080455/AI/NIAID NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- R01 AI095706/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources